1 of 1
Story summary
- Orforglipron, a new weight loss pill, may help individuals with obesity lose up to 20% of their body weight in 72 weeks.
- Eli Lilly's trial involved 3,127 participants across nine countries, testing various doses against a placebo.
- The highest dose (36 mg) led to an average weight loss of 11.2%, with 54.6% of participants losing at least 10%.
- Participants experienced improved blood pressure, waist circumference, and cholesterol levels, though some faced mild to moderate gastrointestinal side effects.
- Orforglipron's oral formulation could enhance accessibility compared to injectable treatments, but it is not yet FDA-approved.
